5-MCT-13-Covid19-Trials-2022

We travel and learn. Meeting new people, in new places reinforces our relationships because we share the good and the hard moments together as a Team.

Our Team in Sub-Saharan Africa is turning the adventure into a real success; each problem is handled as an opportunity to show that our ambition has no limit.

From “the smiling coast”, The Gambia.
Meet our team Aymen Garaali from Tunisia, Nora Mbinglo from Senegal and Mahamadou Kone from Mali.

MCT-Team-2022

MCT-Team-Building-Egypt-2021

MCT-Team-Building-Tunisia-2021

After more than 10 years of continuous growthMCTis now operating in 36 countries acrossMENA&Africa.

Proud to be the largest regionalCROof MENA!
Looking forward to continuedexpansionandgrowth.

During the Sickle Cell Awareness month MCT is proud to contribute to the research to find a treatment for sickle cell disease with hundreds of patients recruited to date.

Sickle-Cell-Awareness-Month

MCT is grateful to Pr. Olayemi and his team at Korle-Bu site in Ghana, for recruiting their first patients on a SCD study.

No doubt the Korle-Bu site will significantly contribute to the success of this study!

Sicke-Cell-Disease-Study-Olayemi

MCT is pleased to announce the recruitment of the first patients at Kintampo site in Ghana, on a promising SCD study. Thanks to Dr. Kaali and his great team, who have made it all possible!

Sickle-Cell-Disease-Study

MCT is currently involved in 5 COVID-19 clinical trials across Africa in 10 countries, (Tunisia, Rwanda, Ghana, Uganda, Kenya, Mozambique, Zimbabwe, Mali, Nigeria, Malawi) and close to 30 sites, aiming at more than 20,000 patients to be vaccinated.

A big thanks to all the PIs and site staff who contribute by their hard work and dedication to make Africa and the world safer.

Covid-19-Clinical-Trials

MCT has been working on a challenging and exciting Lassa Fever study in Ghana.

We’re taking a moment here to congratulate Prof. Koram and his team from the Noguchi MIMR site in Ghana, for their excellent work.

136 patients randomized so far. Keep this amazing pace!

MCT-POST-July-3.1